• PDR Search

    Required field
  • Advertisement
  • FDA Date: 12/08/2017

    Emtricitabine/tenofovir disoproxil fumarate REMS

    Goals of the emtricitabine/tenofovir disoproxil fumarate REMS Program

    The goals of the REMS for TRUVADA for a Pre-Exposure Prophylaxis (PrEP) Indication are:

    To inform and educate prescribers and uninfected individuals at high risk for acquiring HIV-1 infection about:

    • The importance of strict adherence to the recommended dosing regimen

    • The importance of regular monitoring of HIV-1 serostatus to avoid continuing to take TRUVADA for a PrEP indication, if seroconversion has occurred, to reduce the risk of development of resistant HIV-1 variants

    • The fact that TRUVADA for a PrEP indication must be considered as only part of a comprehensive prevention strategy to reduce the risk of HIV-1 infection and that other preventive measures should also be used

    REMS Elements

    • Elements to Assure Safe Use